[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"age-related-cataract\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:age-related-cataract":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100635301","the-impact-of-surgical-procedures-on-postoperative-outcomes-in-cataract-phacoemulsification-and-analysis-of-related-factors-100635301",false,"NCT07550907","The Impact of Surgical Procedures on Postoperative Outcomes in Cataract Phacoemulsification and Analysis of Related Factors","Inclusion Criteria:\n\n* Age ≥ 50 years and ≤ 90 years\n* Diagnosis of unilateral\u002Fbilateral age-related cataract\n* Nuclear grade ≥2 in LOCSIII classification\n* Scheduled for cataract phacoemulsification combined with intraocular lens implantation\n* Pupil size ≥6mm after dilation\n* Corneal endothelial cell count ≥1500 cells\u002Fmm²\n\nExclusion Criteria:\n\n* Diagnosis of severe systemic disease (e.g., severe hypertension or Alzheimer's disease)\n* History of ocular trauma or surgery\n* Presence of other ocular diseases (such as glaucoma, diabetic retinopathy, or high myopia)\n* Other ocular factors that may complicate the surgery (such as small pupil, shallow anterior chamber)","ALL","50 Years","90 Years",{"count":19,"type":20},300,"ESTIMATED","1 Month","OBSERVATIONAL","The goal of this observational study is to evaluate the location of phacoemulsification tip measured by intraoperative OCT during cataract surgeries and its impact on early postoperative changes of cornea and visual acuity. The main question it aims to answer is:\n\nIn patients with age-related cataracts undergoing phacoemulsification, does the location (supracapsular, iris-lens diaphragm, or endocapsular) of the phaco tip affect postoperative corneal changes and visual acuity at early postoperative stage? Eyes having phacoemulsification for cataracts will receive intraoperative OCT imaging to evaluate the location of the phaco tip during surgery, and corneal changes and visual acuity will be measured postoperatively.",[25],"Age-related Cataract","RECRUITING","2026-06-01",{"date":29,"type":30},"2026-06-03","ACTUAL",{"date":32,"type":30},"2026-04-20",{"date":34,"type":20},"2027-06-30",{"name":36,"class":37},"Zhongshan Ophthalmic Center, Sun Yat-sen University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100563298","phase-2-prednisolone-acetate-eye-drops-for-pain-intervention-in-second-eye-cataract-surgery-100563298","NCT06614348","Prednisolone Acetate Eye Drops for Pain Intervention in Second Eye Cataract Surgery","A Randomized Controlled Study of Prednisolone Acetate Eye Drops for Pain Intervention in Second Eye Cataract Surgery","Inclusion Criteria:\n\n* Age between 50-80 years old;\n* A clear diagnosis of age-related cataract, having completed the first eye cataract surgery at our hospital, and planning to have the second eye cataract surgery with the same doctor;\n* The interval between the two surgeries is ≤30 days;\n* Capable of cooperating to complete iris optical coherence tomography angiography examination;\n* Based on our team\\'s previous research, a predictive scoring formula for pain during the second eye surgery has been derived (Predicted score = 1.36 + 4.93 \\* preoperative iris vessel area density - 0.24 \\* surgical interval (weeks)), and the calculated predicted score is \\>2.\n\nExclusion Criteria:\n\n* History of ocular trauma, ocular surgery, uveitis, fundus disease, glaucoma, or recent history of episcleritis, keratitis, severe dry eye, and other ocular surface disease episodes;\n* Participation in intraocular or systemic medication clinical trials within the past 6 months;\n* Having an autoimmune disease or currently undergoing immunosuppressive therapy;\n* Having a psychiatric disorder such as anxiety or depression;\n* History of using glucocorticoid eye drops for treatment in the second eye within the past month;\n* Long-term use of drugs that can cause intraoperative floppy iris syndrome, such as alpha-blockers;\n* Severe complications occurred during or after the first eye surgery (e.g., posterior capsule rupture, zonular exercise, nuclear drop into the vitreous cavity, postoperative endophthalmitis, glaucoma, etc.).","80 Years",{"count":48,"type":20},70,"INTERVENTIONAL",[51],"PHASE2","This study aims to evaluate the efficacy, safety, and potential mechanisms of prednisolone acetate eye drops for pain management in patients undergoing second-eye surgery for age-related cataracts.\n\nResearchers will compare prednisolone acetate eye drops to sodium hyaluronate eye drops to see if prednisolone acetate eye drops work to relieve intraoperative and postoperative pain during second-eye cataract surgery.\n\nParticipants will:\n\n1. Receive prednisolone acetate eye drops or sodium hyaluronate eye drop four drops within 2 hours before cataract surgery\n2. Finish cataract surgery and routine postoperative follow-up\n3. Pain questionnaire completed after cataract surgery",[54,55],"Age Related Cataract","Pain Management During Cataract Surgery",[57,58,59],"cataract surgery","pain","second-eye cataract surgery","NOT_YET_RECRUITING","2024-09-24",{"date":63,"type":30},"2024-09-26",{"date":65,"type":20},"2024-10-08",{"date":67,"type":20},"2025-11-30",{"name":69,"class":37},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":49,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100366390","phase-4-comparison-of-treatment-with-preservative-free-dexamethasone-01-monofree-dexamethason-and-diclofenac-01-dicloabak-eye-drops-versus-preserved-dexamethasone-01-maxidex-and-diclofenac-01-voltaren-ophtha-eye-drops-after-cataract-surgery-100366390","NCT04050644","Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery","GIST","Inclusion Criteria:\n\n* Patients diagnosed with age-related cataract\n* Age 60 years or above\n\nExclusion Criteria:\n\n* Unwilling to sign informed consent\n* Pseudoexfoliation syndrome\n* Functionally monocular patient\n* Any use of eye drops during at least 3 months before surgery with the exception of artificial tears\n* Pre-existing dry eye disease according to the criteria's of the TFOS DEXS II report\n* Previous ocular surgery, laser treatment or uveitis, with the exception of retinal laser treatment (more than 6 months ago) and iridotomy (more than 6 months ago)\n* Active conjunctivitis\n* Wearing of contact lens\n* Presence of any macular diseases possibly impacting visual acuity\n* Presence of any ocular diseases leading to difficulty to have a correct eye examination\n* Known or suspected allergy to any of the ingredients on the study medications\n* Presence of uncontrolled systemic disease","60 Years",{"count":79,"type":20},100,[81],"PHASE4","To compare treatment with preservative-free dexamethasone 0.1% (Monofree Dexamethason) and diclofenac 0.1% (Dicloabak) eye drops versus preserved dexamethasone 0.1% (Maxidex) and diclofenac 0.1% (Voltaren Ophtha) eye drops after cataract surgery in terms of postoperative inflammation, iatrogenic dry eye disease and cystoid macular edema.",[25],[85,86],"Preservative-free ocular drops","Preserved ocular drops","2024-06-28",{"date":89,"type":30},"2024-07-01",{"date":91,"type":30},"2018-10-30",{"date":93,"type":20},"2024-12",{"name":95,"class":37},"Universitaire Ziekenhuizen KU Leuven",2]